VYNE Therapeutics Inc. VYNE
Set alert
28.56 USD 0.00 0.00%
At close · Jul 27
0.65 -27.91 -97.73%
After hours · Jul 27, 4:00 PM ET
23.37 Day range 28.72
0.3208 52-week range 28.56
- YTD
- +4,824.14%
- 1 year
- +1,662.96%
- Open
- 25.50
- Prev close
- 28.56
- Mkt cap
- 19.07M
- Vol
- 93.26K
- Avg vol
- 44.15K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 23.37
- High
- 28.72
- Forward P/E
- -2.95
- Beta
- 1.35
- Short ratio
- 0.65
- Inst. own
- 51.92%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 2.68
- 200-d avg
- 2.31
- 1y target
- 6.19
Key statistics
- Market cap
- 37.91M
- Enterprise value
- -33.18M
- Trailing P/E
- 0.78
- Forward P/E
- -2.95
- PEG ratio
- 0.00
- Price / sales
- 76.90
- Price / book
- 0.60
- EPS (TTM)
- 3.29
- Beta
- 1.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 493.00K
- Revenue growth
- 6.10%
- Free cash flow
- 0
- Total cash
- 70.19M
- Total debt
- 123.00K
- Return on equity
- -90.47%
- Shares outstanding
- 14.75M
- Short % of float
- 0.44%
- 50-day average
- 2.68
- 200-day average
- 2.31
Analyst view
Price target (mean) 6.19 -78.3% downside
Now 28.56
- Target (low)
- 5.00
- Target (mean)
- 6.19
- Target (high)
- 8.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
VYNE Revenue — quarterly 86.00K
VYNE Net income — quarterly -3.58M
VYNE EPS — quarterly -4.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.24 | -0.29 | -0.05 | -20.83% |
| Aug 14, 2024 | Jun 1, 2024 | -0.19 | -0.22 | -0.03 | -15.79% |
| Aug 14, 2024 | Jun 1, 2024 | -0.19 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.24 | -0.15 | +0.09 | +37.50% |
| May 9, 2024 | Mar 1, 2024 | -0.24 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.50 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 18, 2024 | BTIG | init | — | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About VYNE Therapeutics Inc.
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vynetherapeutics.com
News
- Why SAP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Crude Oil Rises Over 1%; General Mills Earnings Top Views
- Dow Jumps 150 Points; Jabil Posts Upbeat Earnings
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on VYNE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DOMZALSKI DAVID T | Chief Executive Officer | Stock Award(Grant) | Nov 28, 2024 | 500,597 |
| HARSCH MUTYA FONTE | General Counsel | Stock Award(Grant) | Dec 28, 2023 | 149,435 |
| LEPORE PATRICK G | Director | Purchase | Nov 14, 2023 | 36,472 |
| STUART IAIN A | Officer | Stock Award(Grant) | Dec 28, 2023 | 133,898 |
| ZERONDA TYLER | Chief Financial Officer | Stock Award(Grant) | Dec 28, 2023 | 131,837 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Eventide Asset Management LLC | 9.45% | 1,394,336 | 3.58M | Sep 29, 2024 |
| Cormorant Asset Management, LP | 9.45% | 1,394,336 | 3.58M | Sep 29, 2024 |
| Citadel Advisors Llc | 8.05% | 1,187,413 | 3.05M | Sep 29, 2024 |
| DSC Advisors, L.P. | 4.72% | 696,465 | 1.79M | Sep 29, 2024 |
| Palo Alto Investors Lp | 3.02% | 445,434 | 1.14M | Sep 29, 2024 |
| Vanguard Group Inc | 3.01% | 443,518 | 1.14M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.53% | 373,319 | 959.43K | Sep 29, 2024 |
| Mutual Fund Ser Tr-AlphaCentric LifeSci Healthcare Fund | 1.82% | 268,485 | 690.01K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 70,144 | 180.27K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.47% | 69,195 | 177.83K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.24% | 35,547 | 91.36K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 21,485 | 55.22K | Oct 30, 2024 |